The results indicated that ATP1A3 and AQP4 colocalized in GBM cells, and both CS‐6 and TMZ monotherapy promoted the activation of ATP1A3 and, together, AQP4 suppression. This evidence concerns the gene ATP1A3 and glioblastoma.